Apotex Corp. announced April 12 the company’s release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.

Cranbury, New Jersey-based Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of the cancer metabolism drug CPI-613 (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.

The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.